Cardiol Therapeutics Inc. Class A · TSX:CRDL

Cardiol Therapeutics Inc. Class A — Technical Presentation (September 2023)

13 slides from Cardiol Therapeutics Inc. Class A's technical presentation, Sep 19, 2023

  1. Slide 1: Impact of CardiolRx on Recurrent Pericarditis

    MAvERIC-Pilot is a Phase 2 multi-center, open-label, pilot Impact of CardiolRx™ study assessing the impact of on Recurrent Pericarditis CardiolRx™ (cannabidiol) oral solution, on recurrent pericarditis ClinicalTrials.gov Identifier: NCT05494788 MAvERIC-Pilot_Study Intro Presentation_19-Sept-23

  2. Slide 2: Introduction

    Introduction Managing recurrent pericarditis which is refractory or intolerant to current treatments is particularly challenging • Current first- and second-line management consists of NSAIDs, colchicine and corticosteroids • Chronic corticosteroid use has been associated with serious adverse effect

  3. Slide 3: The Therapeutic Target

    The Therapeutic Target • Pericarditis is often triggered by a viral infection or pericardial insult, resulting in aberrant activation of the inflammasome signaling pathway • NLRP3 inflammasome protein components are activated which induce the release of pro-inflammatory cytokines (e.g., IL-1α, IL-1β

  4. Slide 4: Study Intervention

    Study Intervention • CardiolRx™ is a pharmaceutically manufactured synthetic cannabidiol solution, formulated for oral administration • Research suggests that the drug substance in CardiolRx™ attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammaso

  5. Slide 5: MAvERIC-Pilot Study Objectives

    MAvERIC-Pilot Study Objectives Efficacy Safety The primary efficacy objective is to evaluate the effect The primary safety objective is to demonstrate that of CardiolRx™ on patient-reported pericarditis pain score administration of CardiolRx™ in the proposed doses using an 11-point Numerical Rating

  6. Slide 6: Study Design

    Study Design • This is a Phase 2 multi-center, open-label, pilot study • Participants will be enrolled in the study for approximately 26 weeks: ‣ 72-hour Screening/Baseline Period ‣ 8-week Treatment Period ‣ 18-week Treatment Extension Period • The dose of CardiolRx™ will be titrated from 5 mg/kg up

  7. Slide 7: Study Schema

    Study Schema a Baseline 72 hrs Day 10 to End of Study 10mg/kg of body weight, BID 7.5mg/kg of body weight, BID 5mg/kg of body weight, BID Dose Escalation (10 days)* Treatment Period 8 Weeks Extension Period 18 Weeks “If the next higher dose is not tolerated, it will be reduced to the previous tolera

  8. Slide 8: Key Inclusion Criteria

    Key Inclusion Criteria: • Male or female patients aged ≥18 years • Diagnosis of at least 2 episodes of recurrent pericarditis • At least 1 day with pericarditis pain score ≥4 on the 11-point NRS within the prior 7 days • CRP ≥1.0 mg/dL OR evidence of pericardial inflammation assessed by delayed peri

  9. Slide 9: Key Exclusion Criteria

    Key Exclusion Criteria: • Diagnosis of pericarditis secondary to the • Current diagnosis of cancer following etiologies: (except for non-melanoma skin cancer) ‣ Tuberculosis • Immunosuppressive therapy with any of the ‣ Neoplastic, purulent or radiation etiology following treatments: ‣ Post-thoracic

  10. Slide 10: What are the potential benefits for participants?

    What are the potential benefits for participants? • Participants’ overall health and pericarditis symptoms will be closely monitored during the study • The results of the study could increase the knowledge about the use of cannabidiol in recurrent pericarditis

  11. Slide 11: What are the potential risks for participants?

    What are the potential risks for participants? • Risks associated with study procedures (e.g. risks of blood sampling, irritation due to ECG pads, etc.) • Potential for hypersensitivity or allergic reaction to the study medicine • Adverse reactions to the study medicine may include: ‣ Diarrhea ‣ Dec

  12. Slide 12: Site Contacts and Referral Information

    Site Contacts and Referral Information If you have patients under your care who may be eligible for this study, please consider them for referral to the participating sites listed below. Pima Heart and Vascular Clinical Research Virginia Commonwealth University Health Tucson, Arizona, United States,

  13. Slide 13: Site Contacts and Referral Information (cont.)

    Site Contacts and Referral Information (cont.) Mayo Clinic Minneapolis Heart Institute Foundation Rochester, Minnesota, United States, 55905 Minneapolis, Minnesota, United States, 55407 Contact: S. A. Luis, MD Contact: David Lin, MD Email: luis.s@mayo.edu Email: David.Lin@allina.com Principal Invest

Cardiol Therapeutics — Technical Presentation (September 2023) on 6ix